Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denikitug Monotherapy or Combination in Advanced HER2-Negative Gastric, GEJ, and Esophageal Adenocarcinomas
NCT07546812Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2026
- Primary completion
- Jan 2030
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of denikitug in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Gilead Sciences. Started Aug 2026; status: recruiting.
02
Drugs
denikitug
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07546812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546812.